The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were ...

Health NGO, Right to Care, highlights the urgent need for circumcision among boys aged 15 and older in KwaZulu-Natal to ...

Overall rates of treatment emergent adverse events (AEs) were 53% for both Dupixent and placebo. AEs more commonly observed with Dupixent (≥5%) compared to placebo included injection site reactions ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy -; similar to that approved by the Food and Drug Administration (FDA) to treat inflammatory ...